MD Biosciences in-licenses intellectual property assets relating to colorectal cancer diagnostic methods of Bio-Marcare Technologies
(Blood-based Colon Cancer Screening Methodology)
October 14, 2016, Weizmann Science Park, Nes Ziona, Israel - MD Biosciences announced today its agreement for the exclusive license rights of all intellectual property assets of Bio-Marcare Technologies, Ltd. that relate to methods for circulating, DNA-based identification of pre-cancerous colorectal polyps and colorectal cancer. This agreement has been reached with Hadasit Medical Research Services and Development Ltd. of the Hadassah Ein Kerem Medical Center in Jerusalem, Israel.
MD Biosciences clinical scientists will be developing the methods towards commercialization at its CLIA clinical laboratories. “We are very excited to move forward with the development of the technology to provide a sensitive and cost-effective method for identifying and monitoring individuals at high risk of colorectal cancer, said Eddie Moradian, Chief Executive Officer of MD Biosciences. “A large percentage of individuals do not readily comply with current colon cancer screening methods and they would readily benefit from our blood-based tests.”
Development work will be carried out at MD Biosciences Innovalora in Israel in conjunction with the MD Biosciences CLIA Clinical Diagnostics Laboratories in Saint Paul, MN.
About MD Biosciences
MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.